



ASX Announcement

16th May 2024

Significant funding committed to HIV Self-Testing in the Federal Budget

SYDNEY Australia, 16th May 2024 – Atomo Diagnostics Limited (ASX:AT1) (Atomo) welcomes the Australian Federal government’s commitment to fund expansion of HIV Self-Testing in the Budget.

- *People with or at risk of HIV will receive unprecedented support (\$43.9 million) through better prevention, testing, workforce training and information, with the Government committed to eliminating HIV transmission by 2030.*
- *More people in at-risk groups will get free HIV self-test kits through the expanded national HIV self-test mail-out program.*
- *People around Australia will get wider access to HIV testing by extending the South Australia-based HIV testing vending machine pilot to every state and territory.*

<https://www.health.gov.au/sites/default/files/2024-05/budget-2024-25-ensuring-all-australians-get-the-health-care-they-need.pdf>

Atomo supplies the only HIV Self-Test included on the Australian Register of Therapeutic Goods (ARTG) and has been instrumental in the implementation of these pilot programs, now being scaled nationally through funding support from the Federal Government. Atomo anticipates that a significant portion of the funding committed to these expanded HIV Self-Test programs will be used for procurement of Atomo HIV tests.

The funding of expanded HIV self-test access in the budget comes after the Australian Government’s HIV Taskforce, in November last year, recognised for the first time the critical role HIV self-testing plays in enabling Australia to reach its HIV targets. Atomo remains committed to continuing to work Government and other stakeholders to ensure access to quality HIV self-tests is not a barrier to Australia reaching its 2030 goals.

Atomo CEO John Kelly said: “We are delighted to see the government recognise the critical need to ensure HIV Self-Test availability across the community and fund the rapid expansion of the national HIV self-test mail-out program and the HIV self-test vending machine pilots. Both have proven extremely successful in increasing testing rates among groups not currently testing via healthcare facility-based services.”



For more information, please contact:

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com